Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
WEST LAFAYETTE, Ind., March 02, 2017 -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Friday, March 10th, at 8:30 a.m. EST to discuss its fourth quarter and full year financial results and provide an operational update.
Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investors & News section of the Company’s website at www.endocyte.com or by dialing (877) 845-0711 (U.S./Canada) or (760) 298-5081 (International).
The webcast will be recorded and available on the Company’s website for 90 days following the call.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company’s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at www.endocyte.com.
Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
